Pipe

R&D ea Sorrento e tsepamisitse maikutlo ho nts'etsopele ea boqapi ho COVID-19, kalafo ea mofets'e, taolo e felletseng ea bohloko le mafu a autoimmune.

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
Mananeo a COVID-19  

COVISTIX™ (tlhahlobo) Tlhahlobo e potlakileng ea Antigen

*

Tumello ea Tšebeliso ea Tšohanyetso (EUA) Mexico (COFEPRIS), Brazil (ANVISA), le CE E tšoauoa Europe

COVIMARK™ (tlhahlobo) Tlhahlobo e potlakileng ea Antigen

*

Kopo e rometsoe US le Canada bakeng sa Tumello ea Tšebeliso ea Tšohanyetso (EUA)

VIREX (tlhahlobo) Ka Lapeng Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (kalafo) Antibody e Neutralizing (IV) ho Bakuli ba ka Ntle le Bakuli ba ka Lapeng

20%*

FUJOVEE™ (Abivertinib) COVID-19 e matla ho Bakuli ba ICU

82%*

Teko ea Bohlokoa e Emetseng ho Hlakoloa ha FDA

OQORY™ (COVI-MSC) ARDS ka lebaka la COVID-19 ho Bakuli ba ICU

82%*

Teko ea Bohlokoa Brazil

Mlan Inhibitor (pilisi ea molomo) Khahlano le bongata

40%*

Ente ea Omicron mRNA ente

20%*

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*Ka Tšebelisano le Lee's Pharm naheng ea China

PD-L1 (STI-3031)** Kankere ea Mokokotlo

82%*

**Naheng ea Amerika le ka kopanelo le ImmuneOncia ea Korea

CD47 Lihlahala tse Tiileng

40%*

CD38 DAR-T Myeloma e ngata

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, le esophageal

40%*

Seprehvec™ oncolytic virus Lihlahala Tse Tiileng; Lihlahala tsa CNS

40%*

BCMA ADC Lihlahala tsa Metsi

20%*

Bevacizumab-ADAB™ Kankere ea Endometrial

40%*

Ka kopanelo le Mayo Clinic

Bevacizumab-ADAB™ Cancer ea kankere ea mahe

40%*

Ka kopanelo le Mayo Clinic

Rituximab-ADAB™ B-cell Lymphomas

40%*

Ka kopanelo le Mayo Clinic

Sofusa® anti-PD-1 T-Cell Lymphoma (CTCL), Melanoma

40%*

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
Bohloko  

ZTlido® 1.8%
Neuralgia ea Postherpetic - PHN

99.8%*

Gloperba®
Kalafo ea Gout (Oral)

99.8%*

SEMEXA (SP-102) Bohloko ba Lumbar Radicular / Sciatica

82%*

Sp,-103 (Lidocaine Topical System 5.4%) Mahlaba a Acute Back Back

60.2%*

Sp,-104 (Naltrexone e Liehisitsoe ho Burst Low) Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural ente
Bohloko bo ke keng ba Rarolloa ho Kankere e Tsoetseng Pele

60.3%*

Lebitso la khutsana

RTX (resiniferatoxin)
Tsela e ka hare-hare
Bohloko bo Itekanetseng ho isa ho Bohlokoa Knee

60.2%*

Mananeo a Bohlokwa Tlhaloso Pele ho tlhokomelo Karolo ea I Mothati oa II Mokhahlelo oa III/Bohlokoa FDA Approval
Phano ea Lithethefatsi tsa Lymphatic  

Sofusa® -ba khahlanong le TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® khahlanong le CTLA-4 Melanoma

40%*

Ka kopanelo le Mayo Clinic
Mananeo a COVID-19
Mananeo a Bohlokwa (Tlhahiso) Phase
COVISTIX™ (tlhahlobo) FDA EUA
COVIMARK™ (tlhahlobo) FDA EUA
VIREX (tlhahlobo) PH III
COVISHIELD™ (kalafo) PH ke
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mlan Inhibitor (pilisi ea molomo) Ph II
Ente ea Omicron mRNA Pele ho tlhokomelo
immunotherapy
Mananeo a Bohlokwa (Tlhahiso) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) Pele ho tlhokomelo
FUJOVEE™ (Abivertinib) Pele ho tlhokomelo
EA-L1 (Socazolimab)* Ph III
EA-L1 (STI-3031)** Ph III
CD47 (Lihlahala tse tiileng) Ph I
CD38 DAR-T Myeloma e ngata Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, le esophageal) Ph I
Seprehvec™ oncolytic virus (Lihlahala tse tiileng; CNS Tumors) PH ke
BCMA ADC (Lihlahala tsa Metsi) Pele ho tlhokomelo
Bevacizumab-ADAB™ (Kankere ea Endometrial) Ph I
Bevacizumab-ADAB™ (Kankere ea Ovary) Ph I
Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 T-Cell Lymphoma (CTCL), Melanoma Ph I
Bohloko
Mananeo a Bohlokwa (Tlhahiso) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Kalafo ea Gout (Oral) FDA Approval
SEMEXA (SP-102) Ph III
Sp,-103 (Lidocaine Topical System 5.4%) Ph II
Sp,-104 (Naltrexone e Liehisitsoe ho Burst Low) Pele ho tlhokomelo
RTX (resiniferatoxin) Epidural ente Ph II
RTX (resiniferatoxin) Tsela e ka hare-hare Ph II
Phaliso ea Lymphatic
Mananeo a Bohlokwa (Tlhahiso) Mothati oa II
Sofusa® -ba khahlanong le TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 T-Cell Lymphoma (CTCL), Melanoma Ph I
Sofusa® khahlanong le CTLA-4 (Melanoma) Ph I